资源描述：
《聚乙二醇干扰素α―2a单用及联用胸腺法新治疗慢性丙型病毒.doc》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。
1、聚乙二醇干扰素a-2a单用及联用胸腺法新治疗慢性丙型病毒［摘要］目的评价聚乙二醇干扰素a-2a(PegTNFa-2a)单用及联用胸腺法新治疗慢性丙型病毒性肝炎的疗效和安全性。方法74例慢性丙型病毒性肝炎患者随机分为两组：PeglNFa-2a组；PeglNFa-2a+胸腺法新组。比较两组治疗早期和治疗结束时生物化学应答率和病毒学应答率、持续生物化学应答率和复发率、持续病毒学应答率和复发率。结果PeglNFa-2a组治疗早期生物化学应答率、治疗结束吋生物化学应答率、持续生物化学应答率和复发率分别为5
2、0.0%、76.2%.78.6%和15.6%；治疗早期病毒学答率、治疗结束时病毒学应答率、持续病毒学应答率和复发率分别为47.6%、76.2%.73.8%和15.6%；PegTNFa-2a联合胸腺法新治疗组治疗早期生物化学应答率、治疗结束时生物化学应答率、持续生物化学应答率和复发率分别为53.0%.93.8%.96.9%和0%；治疗早期病毒学应答率、治疗结束时病毒学应答率、持续病毒学应答率和复发率分别为50.0%、93.8%、93.8%和0%。两组治疗早期各指标无统计学差异(P>0.05),治疗
3、结束时各指标有统计学差异(P〈0・05)o结论PeglNFa-2a能有效治疗慢性丙型病毒性肝炎，联用胸腺法新能增强疗效。［关键词］丙型病毒性肝炎；聚乙二醇干扰素；胸腺法新；效果［中图分类号］R512.63［文献标识码］B［文章编号］1673-9701(2016)10-0037-04[Abstract]ObjetiveToevaluatetheeffectsandsafetyofpeginterferona-2amonotherapj^andcombinedtherapyofthymalfasin
4、forthetreatmentofchronichepatitisC.MethodsSeventy-fourchronichepatitisCpatientswereassignedrandomlyintotwogroups:peginterferona-2a；peginterferona-2a+thymalfasin.Earlybiochemicalresponserates,endoftreatmentbiochemicalresponse,sustainab1ebiochemicalres
5、ponse,biochemicalrecurrencerates,earlyvirologicalresponserates,endoftreatmentvirologicalresponse,sustainablevirologicalresponse,virologicalrecurrencerates,ratesofadverseeffectswereanalyzed.ResultsInthepeginterferona-2agroup,earlybiochemicalresponsera
6、tes,endoftreatmentbiochemicalresponse,sustainablebiochemicalresponse,biochemicalrecurrencerateswere50.0%,76.2%,78.6%and15.6%respectively；earlyvirologicalresponserates,endoftreatmentvirologicalresponse,sustainablevirologicalresponse,virologicalrecurre
7、ncerateswere47.6%,76.2%,73.8%and15.6%respectively；Inthepeginterferona-2a+thymalfasingroup,earlybiochemicalresponserates,endoftreatmentbiochemicalresponse,sustainablebiochemicalresponse,biochemicalrecurrencerateswere53.0%,93.8%,96.9%and0%respectively,
8、earlyvirologicalresponserates,endoftreatmentvirologicalresponse,sustainab1evirologicalresponse,virologicalrecurreneerateswere50.0%,93.8%,93.8%and0%respectively.Therewerestatisticaldifferencesbetweentheparametersattheendofthetreatment(P0.05)・Conclusio
